Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, and Colorectal and Anal Carcinomas.
Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29).
A Phase 2 Study of Stereotactic Ablative Radiotherapy Plus Atezolizumab Plus Tiragolumab in Treatment-naïve Patients with Advanced Non-small Cell Lung Cancer.
JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Supplementary Figure S1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Table S3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Table 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Table S1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Figure S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Table 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Figure 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Figure 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Figure S3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Table S5 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Table S4 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Table S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Data from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Figure 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Table 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).
Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
Single-cell multi-omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK-positive lung cancer.
LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study
4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial.